The vaccinia virus E3L gene product, pE3, is a dsRNA binding protein that prevents activation of the interferon-induced, dsRNA-activated protein kinase, PKR. Activation of PKR, which results in phosphorylation of the translation initiation factor, eIF2␣, leads to the inhibition of protein synthesis, a process involved in defense against virus infection. The E3L gene product has a conserved dsRNA binding domain (DRBD) in its carboxyl-terminal region and has been shown to function in vitro by sequestration of dsRNA. We have utilized in vitro binding assays and the yeast two-hybrid system to demonstrate direct interactions of pE3 with PKR. By these methods, we demonstrate that pE3 interacts with two distinct regions in PKR, the amino-terminal (amino acids 1±99) located in the regulatory domain and the carboxyl-terminal (amino acids 367±523) located in the catalytic domain. The amino-terminal region of PKR that interacts with pE3 contains a conserved DRBD, suggesting that PKR can form nonfunctional heterodimers with pE3, analogous to those seen with other dsRNA binding proteins. Interaction of pE3 with the amino-terminal region of PKR is enhanced by dsRNA. In contrast, dsRNA reduces the interaction of pE3 with the carboxyl-terminal region of PKR. Competition experiments demonstrate that the carboxyl-terminal region of PKR, to which pE3 binds, overlaps the region with which eIF2␣ and the pseudosubstrate pK3 interact, suggesting that pE3 may also prevent PKR activation by masking the substrate binding domain. Like pE3, the amino-terminal region of PKR also interacts with the carboxyl-terminal domain of PKR. These interactions increase our understanding of the mechanisms by which pE3 downregulates PKR. In addition, the PKR±PKR interactions observed leads us to suggest a novel autoregulatory mechanism for activation of PKR in which dsRNA binding to the DRBD(s) induces a conformational change that results in release of the amino terminal region from the substrate binding domain, allowing access to eIF2␣ and its subsequent phosphorylation.
INTRODUCTION
The interferon-induced, dsRNA-dependent serine/ threonine protein kinase, PKR, 3 contributes significantly to the establishment of the antiviral state by interferon (Katze, 1995; Mathews, 1996; Samuel et al., 1997) . PKR regulates the initiation of protein synthesis through phosphorylation of the ␣ subunit of the protein synthesis initiation factor eIF2 (Clemens, 1996; DeHaro, 1996; Clemens and Elia, 1997; Samuel et al., 1997) . PKR levels are upregulated by interferon although the kinase is expressed constitutively by many cell types (Clemens and Elia, 1997; Samuel et al., 1997) . PKR is activated in vitro and in virus-infected cells by dsRNA (Mathews, 1996; Clemens and Elia, 1997; Samuel et al., 1997) , the binding of which activates PKR, leading to a conformational change, autophosphorylation, and the formation of a homodimeric state (Galabru and Hovanessian, 1987; Cosentino et al., 1995; Patel et al., 1995; Wu and Kaufman, 1996; Carpick et al., 1997) . The dsRNA binding domain of PKR maps to the amino-terminal 170 amino acids Feng et al., 1992; Green and Mathews, 1992; McCormack, et al., 1992; Patel and Sen, 1992) . This region contains two copies of a 65-amino-acid dsRNA binding motif, rich in basic amino acids, separated by a short spacer. Such motifs have been found in a number of modular dsRNA-binding proteins that exhibit diverse functions (St. Johnson et al., 1992; Bycroft et al., 1995; Kharrat et al., 1995) . These include the Drosophila staufen protein, Escherichia coli RNase III, and dsRNAadenosine deaminases (St. Johnson et al., 1992; Kim et al., 1994; Kharrat et al., 1995; O'Connell et al., 1995) . The two motifs in PKR have been termed DRBD1 (amino acids 10±75) and DRBD2 (amino acids 100±165), although the consensus sequences within these motifs run from residues 55±75 and 145±165 (Green and Mathews, 1992; McCormack, et al., 1992) . DRBD1 more closely matches the dsRNA binding motif consensus sequence and has been shown to be necessary and sufficient for dsRNA binding (McCormack et al., 1994; McMillan et al., 1995; Schmedt et al., 1995; Patel et al., 1996) . Both activation and dimerization are mediated through the dsRNA binding regions (Cosentino et al., 1995; Patel et al., 1995 Patel et al., , 1996 Ortega et al., 1996; Wu and Kaufman, 1996) . However, dimerization between these domains may occur via protein±protein interaction(s) as well as via interaction with dsRNA (Patel et al., 1996; Wu and Kaufman, 1996) . A truncated form of PKR representing amino acids 228±551 [des-(1±227)-PKR], is constitutively active (Wu and Kaufman, 1997) . This observation has led to the proposition that the dsRNA binding domains serve to inhibit the activity of PKR and that dsRNA binding induces a conformational change that exposes the dimerization and autophosphorylation sites, leading to PKR activation (Taylor et al., 1996; Carpick et al., 1997; Wu and Kaufman, 1997) .
Like many eukaryotic protein kinases, PKR is subject to several layers of cellular regulation including transcriptional activation (Tanaka and Samuel, 1994; Samuel and Ozata, 1996) , association with cellular regulators (Lee and Katze, 1993; Ito et al., 1994; Lee et al., 1994; Polyak et al., 1996) , and phosphorylation by other kinases (Taylor et al., 1996) . In addition, PKR is a target for regulation by virally encoded inhibitory molecules (Katze, 1993; Jagus and Gray, 1994; Mathews, 1996) , reflecting the fact that the susceptibility of a virus to the antiviral effects of interferon appears to correlate inversely with its ability to downregulate PKR (Meurs et al., 1992; Beattie et al., 1995a,b) . Vaccinia virus contains two genes, E3L and K3L, that are expressed early in vaccinia virus infection and that encode products able to downregulate PKR activity (Carroll et al., 1993; Davies et al., 1992 Davies et al., , 1993 . Consistent with their ability to downregulate PKR, the products of the E3L and K3L genes contribute to the ability of vaccinia virus to multiply in interferon-treated cells (Beattie et al., 1991 (Beattie et al., , 1995a Jagus and Gray, 1994; Chang et al., 1995) .
The E3L gene encodes a polypeptide of 190 amino acids (25 kDa) that contains one copy of a conserved DRBD and is thus a member of the same dsRNA binding protein family as PKR (Chang et al., 1992; Chang and Jacobs, 1993; Jacobs and Langland, 1996) . The dsRNA binding domain of pE3 lies in the carboxyl-terminal region of the protein, running from amino acids 118±186 Ho and Shuman, 1996a,b) . The E3L gene product corresponds to the activity found in vaccinia virus-infected cells described as specific kinase inhibitory factor (SKIF) (Whitaker-Dowling and Youngner, 1984; Akkaraju et al., 1989) . pE3 functions in vitro as a dsRNA binding protein to sequester the dsRNA and downregulate PKR with a potency similar to that of pK3 (Akkaraju et al., 1989; Chang et al., 1992; Chang and Jacobs, 1993; Jagus and Gray, 1994; Ho and Shuman, 1996b) . Furthermore, transient expression of the E3L gene in vivo stimulates translational expression of a reporter gene and reduces eIF-2␣ phosphorylation (Davies et al., 1993) . In addition, expression of pE3 is able to inhibit the dsRNA-dependent 2Ј-5Ј oligoadenylate arm of the interferon induced host defense pathway (Rivas et al., 1998) . The involvement of pE3 in the downregulation of host defense mechanisms during vaccinia virus infection is supported by the findings that pE3 accumulates early in vaccinia virus infection (Beattie et al., 1995a; Jagus and Gray, 1994) and that E3L deletion mutants of vaccinia virus are less able to grow in interferon-treated cells (Beattie et al., 1995a; Chang et al., 1995) . In vaccinia virus devoid of the E3L gene, resistance to interferon can be restored by the expression of E3L as a transgene (Chang et al., 1995) or by the ectopic expression of other dsRNA binding proteins such as the reovirus 3 protein (Beattie et al., 1995b) , rotavirus NSP3 , TRBP (Park et al., 1994) , or E. coli RNase III . The complementation data demonstrate that the dsRNA binding property of pE3 must be retained for the protein to restore interferon resistance to vaccinia virus .
The HIV TAR-RNA binding protein (TRBP), like pE3 can function to bind dsRNA. TRBP can also interact with the dsRNA binding region of PKR to form heterodimers and inhibit PKR activity (Benkirane et al., 1997; Cosentino et al., 1995) . To determine whether pE3 has a similar capability and to extend our understanding of the mechanism(s) of vaccinia virus-mediated inhibition of PKR, we have undertaken a structural analysis to determine the regions within PKR with which pE3 interacts. Using both in vitro and in vivo binding assays, we have identified two regions within PKR that bind to pE3, one of which involves the dsRNA binding region of PKR and another that overlaps the region of interaction with the substrate eIF2␣ and the pseudosubstrate, pK3. The interactions of pE3 with PKR suggest that it can inhibit PKR activity not only by sequestering dsRNA but also by direct interaction with the regulatory domain of the kinase and/or by interference with substrate binding. These data extend our understanding of the mechanism of PKR downregulation by vaccinia virus pE3 and in so doing expand our understanding of viral strategies that lead to PKR downregulation. The surprising interaction of pE3 with the substrate binding domain of PKR led us to examine interactions between different domains of PKR itself. Analogous to the interaction of pE3 with the substrate binding domain of PKR, the amino-terminal region of PKR was itself found to interact with the carboxyl-terminal region in the yeast two-hybrid system. This interaction suggested a novel intrasteric autoregulatory mechanism for PKR with dsRNA binding causing a conformational change and dimerization between the DRBDs of two PKR molecules that relieves the masking of the substrate binding domain of PKR by its own amino-terminal region.
RESULTS
pE3 binds to wild-type PKR in vitro pE3 has been thought to function primarily as a dsRNA binding protein (Jagus and Gray, 1994; Jacobs and Langland, 1996; . To determine whether pE3 also has the capacity to interact directly with PKR, like other dsRNA binding proteins, in vitro binding studies were performed using immunopurified PKR from HeLa cells and 35 S-labeled pE3. Because a low level of nonspecific binding of 35 S-labeled pE3 to mAB-conjugated Sepharose beads was found to occur, all experiments included a control without PKR but with the antibody bound to beads. The nonspecific binding of 35 S-labeled pE3 to PKR mAB linked to beads was not different from nonspecific binding of S-labeled pE3 bound to PKR from interferon-treated HeLa cells immobilized on mAB-conjugated Sepharose beads. The results were compared to a control using the mAB-conjugated Sepharose beads only. The bar graph below the image panel displays radioactive protein bound, expressed as arbitrary units, as determined using a Storm 840 Phosphoimager. Two forms of the E3L gene product were produced in the in vitro transcription/translation reaction both of which bound PKR. The larger product, at 25 kDa, represents the full-length product of the E3L open reading frame. A smaller polypeptide (20 kDa) is thought to be the product of translational initiation from the first AUG downstream from the initiation codon (Chang et al., 1992; Yuwen et al., 1993) . Both forms have been shown to bind dsRNA (Chang et al., 1992) . The relative level of the smaller polypeptide produced varied with reticulocyte lysate batch used (data not shown). In these assays, Ͼ95% of PKR in the HeLa extracts bound to the beads (data not shown) as did 15±20% of 35 Slabeled pE3.
pE3 binds both the regulatory and catalytic domains of PKR in vitro
To characterize the domains of PKR within which pE3 binds, a series of in vitro binding assays was performed. 35 S-labeled pE3 was examined for its ability to interact with the PKR variants, (Arg296)PKR, PKR⌬6, PKR1±296, and PKR242±551, in an in vitro binding assay (Fig. 2) . pE3 bound to all four PKR variants. The ability of pE3 to interact directly with PKR and PKR1±296 is a novel finding but consistent with the homodimerization of PKR and similar to the heterodimerization of TRBP to PKR through the dsRNA binding motif(s) (Cosentino et al., 1995; Patel et al., 1995 Patel et al., , 1996 Ortega et al., 1996) . However, the interaction of pE3 with PKR242±551 is surprising and suggests that downregulation of PKR activity by pE3 35 S-pE3, synthesized in coupled transcription/translation assays (Promega TNTQuick), was incubated with anti-PKR mAB±Sepharose beads, either bound, or not bound (beads only) to HeLa PKR, for 2 h at 4°C with rotation, as described under Materials and Methods. The beads were rinsed extensively and bound protein was eluted with SDS±PAGE sample buffer and subjected to 17.5% SDS±PAGE, using a Tris±Tricine buffer system (Schagger and von Jagow, 1987) . The radiolabeled protein was visualized using a Storm 840 Phosphoimager and quantified with ImageQuant software. The bar graphs below each image panel indicate the level of radioactive protein bound. through direct interaction might also occur via a mechanism distinct from the formation of inactive heterodimers with the dsRNA binding regions of PKR or via dsRNA sequestration. Since PKR242±551 does not bind dsRNA Patel and Sen, 1992) , this interaction must represent a protein±protein interaction. In contrast, our previous studies using the same PKR constructs have shown that pK3 binds (Arg296)PKR, PKR⌬6 and PKR246±551, but not the amino terminal half of PKR from amino acids 1±296 (Sharp et al., 1997) .
To examine further the molecular determinants within PKR to which pE3 interacts, an additional set of PKR variants expressed as fusion proteins with the 26-kDa glutathione S-transferase were produced; GST-(Arg296)PKR, GST-PKR1±99, GST-PKR99±551, and GST-PKR1±523. The production of fusion proteins was verified by SDS±PAGE and Western blot analysis of cleared cell extracts using an anti-GST antibody (Fig. 3A) . In Fig. 3A , the arrows denote the positions of the PKR fusion proteins based on their predicted molecular weights. Smaller polypeptides represent amino-terminal degradation products. In vitro binding assays using these GSTfusions and 35 S-labeled pE3 were performed (Fig. 3B ). pE3 bound to PKR1±99, consistent with an interaction through the dsRNA binding motif. However, pE3 did not bind above control levels to PKR99±551 (Fig. 3B ). This is in contrast to its ability to interact with PKR242±551 as shown in Fig. 2 . This could be explained if the fusion of the GST binding domain to PKR99±551 interfered with its interaction with pE3. Alternatively, the recombinant protein may not fold properly or retain full biological activity. In summary, pE3 binds in vitro to two regions within PKR; amino acids 1±99, which encompass the first dsRNA binding domain of PKR, and a second region from amino acids 242±523, which covers all of the catalytic subdomains (I-XI) (Meurs et al., 1990) .
Competition of 35 S-labeled pE3 binding to PKR with nonlabeled pE3 and pK3
To verify the ability of pE3 to interact with distinct sites in the amino and carboxy regions of PKR, an excess of nonlabeled recombinant pE3, pK3, and pK3⌬GYID were included in the binding assays (Fig. 4) . pE3 was able to compete with 35 S-labeled pE3 for binding to PKR1±296 and PKR242±551. pK3 was also able to compete with 35 S-labeled pE3 for binding to PKR242±551 but not with binding to PKR1±296, suggesting that pE3 binds to a region in the catalytic domain that is the same, or overlaps, the substrate binding domain. As a further demonstration of the specificity of the interactions of pE3 with PKR subdomains, the ability of the peptide VKVIRVDYT-KGYID (Research Genetics, Huntsville, AL) to compete for the binding of 35 S-labeled pE3 was determined. This peptide corresponds to amino acids 65±78 of pK3, the region most highly conserved between pK3 and eIF2␣ (Goebel et al., 1990) . In eIF2␣, this region lies 30 amino acids in a carboxyl-terminal direction from the phosphorylation site and encompasses the molecular determinants recognized by PKR (Kawagishi-Kobayashi et al., 1997; Sharp et al., 1997) . This peptide was able to compete with 35 S-labeled pE3 for binding to PKR242±551 but
Binding of 35 S-labeled pE3 to GST-fusion proteins. (A) Western blot analysis of GST-fusion proteins. BL21 extracts from cells expressing GST or the GST-fusion proteins were subjected to 12.5% SDS±PAGE and transferred to Immobilon-P. Specific GST products were detected using goat anti-GST polyclonal antibody, followed by rabbit anti-goat HRP-conjugated antibody. Proteins were visualized using the Amersham ECL kit as per the manufacturer's recommendations. Arrows indicate the positions to which GST or GST-fusion proteins should migrate from their predicted molecular weights. All other bands represent degradation products. (B) Binding of 35 S-labeled pE3 to GST-fusion proteins: 35 S-labeled pE3, synthesized as described in the legend to Fig. 1 , was incubated with GST or the indicated GST±PKR variants attached to glutathione±Sepharose beads as described under Materials and Methods. Radioactive protein was eluted with SDS±PAGE sample buffer and subjected to SDS±PAGE. After fractionation by 17.5% SDS±PAGE, as described in the legend to Fig. 1 not with binding to PKR1±296. The ability of nonlabeled pK3⌬GYID to compete for the binding of 35 S-labeled pE3 was also determined. In contrast to pK3, pK3⌬GYID, which lacks part of the region to which PKR interacts, was unable to compete with 35 S-labeled pE3 for binding to either PKR truncation product. These results lend support to the findings that pE3 interacts with the both the dsRNA binding domain of PKR and with a domain in the carboxyl-terminus that is the same as, or overlaps with, the pK3/eIF2␣ binding site.
Effects of dsRNA on the interaction of 35 S-labeled pE3 binding to PKR To test the idea that complex formation between pE3 and domains of PKR is dependent on dsRNA binding, the effects of increasing concentrations of poly(I).poly(C) (0± 200 ng/ml) on the interaction of 35 S-labeled pE3 with wild-type PKR, PKR1±296, and PKR242±551 was determined (Fig. 5) . Binding of 35 S-labeled pE3 to all forms of PKR occurred without the addition of dsRNA. However, binding of 35 S-labeled pE3 to wild-type PKR and PKR1± 242 was stimulated slightly by the inclusion of poly(I-).poly(C). In contrast, the addition of poly(I).poly(C) reduced the interaction of 35 S-labeled pE3 with PKR242± 551. Not only does this demonstrate that dsRNA-binding activity is not required for dimerization of pE3 with the carboxyl-terminal region, it also suggests that dsRNA will favor the formation of pE3 homodimers (or heterodimers with the DRBD of PKR) and thus release of pE3 from the substrate binding domain.
Interaction of pE3 with PKR in the yeast two-hybrid system
To substantiate the data obtained from the in vitro binding analysis, the yeast two-hybrid system was used to monitor the interactions of pE3 with PKR in vivo (Fields and Song, 1989; Iwabuchis et al., 1993) . In this assay the proteins of interest are expressed as GAL4 DNA-binding or GAL4 transactivation domain fusion proteins, and their interaction results in the expression of ␤-galactosidase, which can be assayed using ONPG as a substrate. As predicted from the in vitro binding assays (Figs. 2 and 3B ), pE3 interacted with the full length (Arg296)PKR, as well as PKR1±296 and PKR1±99 in vivo (Table 1) . In contrast to the results from the in vitro binding assays, interaction of pE3 was also detected with PKR99±551. PKR367±551 was also found to interact with pE3, corroborating the conclusions from the in vitro binding and competition data. Last, pE3 was shown to undergo homodimerization in vivo, which is also consistent with in vitro binding data (Ho and Shuman, 1996b) . Note that in these experiments, the E3L gene was expressed in the plasmid containing the GAL4 activation domain and the PKR sequences were expressed in the plasmid containing the GAL4 binding domain. The interaction of pE3 with PKR367±551 was not so apparent when the constructs were expressed from the alternate plasmids (data not shown).
To provide a positive control and a contrast with the pE3 data, the interaction of pK3 with PKR and its variants in the yeast two-hybrid system is also shown (Table 1) . Consistent with previous results (Cosentino et al., 1995; Craig et al., 1996; Gale et al., 1996) , pK3 interacted with the full-length variant (Arg296)PKR and the carboxyl terminal variants PKR242±551 and PKR367±551 (Craig et al., 1996; Gale et al., 1996) . In contrast, pK3 did not interact with PKR1±99 or PKR1±296. No evidence for homodimerization of pK3 was detected in this in vivo system.
Interaction of amino-and carboxyl-terminal domains of PKR in the yeast two-hybrid system
The interaction of pE3 with the carboxyl-terminus of PKR is surprising. This region of PKR from amino acids 35 S-labeled pE3, was synthesized, as described in the legend to Fig. 1 , and incubated with Sepharose beads prebound to the appropriate antibodies (see Materials and Methods), either bound or not bound (beads only) to wild-type PKR or the indicated PKR variants, in the presence or absence of a 50ϫ molar excess of nonlabeled pE3, pK3, or pK3⌬GYID, or 1 mM VKVIRVDYTKGYID. Radioactive protein bound was eluted and quantitated as described in the legend to Fig. 1 . INPUT: represents 20% of total 35 S-labeled protein used in each assay.
367±551 overlaps with the region of pK3 and eIF2␣ interaction and therefore includes the substrate binding domain (Craig et al., 1996; Kawagishi-Kobayashi et al., 1997; Sharp et al., 1997) . Since we assumed that pE3 is functionally equivalent to DRBD1 of PKR, it was tempting to speculate that the homologous regions in PKR, amino acids 55±75 (DRBD1) could give a similar result. This hypothesis was tested using the yeast two-hybrid system. Table 2 illustrates the interaction of domains in the amino and carboxyl-termini of PKR. PKR1±296 was found to interact with PKR367±551. Similarly, PKR1±99 and PKR1±152, each of which contains DRBD1, interacted not only with each other and full-length PKR but also with PKR367±551. This interaction between the regulatory and catalytic domains of PKR parallels the interaction of pE3 with the PKR367±551 and raises the possibility that interaction between the two halves of PKR may fulfill a regulatory function.
DISCUSSION
pE3 plays an important role in the ability of vaccinia virus to grow in interferon treated cells, in part by its ability to downregulate PKR (Beattie et al., 1991 (Beattie et al., , 1995a Chang et al., 1995; Shors and Jacobs, 1997a; . It has been widely considered that the mechanism of pE3's ability to downregulate PKR lies solely in its capacity to sequester dsRNA. We considered the alternative possibility that inhibition of PKR by pE3 could involve complex formation between the two proteins. The data presented here demonstrate that pE3 can interact directly with PKR. A summary of the interactions of pE3 with PKR from both in vitro and in vivo studies is presented in Fig. 6 and is compared with the interactions of pK3 with PKR. Clearly, pE3 is capable of direct interaction with PKR both in vitro and in vivo. The location of sites within PKR that interact with pE3 have been mapped to distinct amino-and carboxyl-terminal regions of the kinase. In comparison, pK3 interacts with the substrate binding domain only. The ability of pE3 to interact with the amino terminal region of PKR (PKR1±99) is consistent with the interaction of dsRNA binding regions within each protein and suggests that pE3 can downregulate PKR by forming nonfunctional heterodimers. The interaction between pE3 and the DRBD of PKR appears to be stimulated by dsRNA (Fig. 4) and is equivalent to the heterodimerization of TRBP to PKR (Cosentino et al., 1995; Benkirane et al., 1997) . A similar interaction underlies the ability of pE3 to form homodimers (Table 1 and Ho and Shuman, 1996b) . The molecular basis of the interaction of pE3 with the substrate binding domain of PKR is less clear but may resemble a previously undiscovered interaction between the regulatory and kinase domains of PKR (Table 2) .
The relative importance of these two properties of pE3, the ability to bind dsRNA and the ability to form nonfunctional heterodimers, to the maintenance of an inactive state of PKR during vaccinia virus infection is not known. A similar uncertainty exists over the ability of enzymatically inactive variants of PKR to downregulate wild-type PKR activity in transfected mammalian cells (Clemens and Elia, 1997) . However, in yeast there is evidence demonstrating that dominant interference by nonfunctional PKR variants involves the formation of defective heterodimers rather than sequestration of dsRNA (Romano et al., 1995) . Such a mechanism provides a more effective means for maintaining PKR in an inactive state because although a small concentration of free dsRNA can activate PKR, the enzyme is less easily activated once nonfunctional heterodimers are formed (Romano et al., 1995) . The formation of inactive heterodimers could provide protection against other cellular mechanisms for activation of PKR analogous to the activation observed in vitro by heparin (George et al., 1996) . Although it is clear that the dsRNA binding region of pE3 is essential for expression of the protein to restore interferon resistance to E3L-deficient vaccinia virus , the genetic dissection of pE3 into dsRNA binding and dimerization domains has only just begun. It has been shown that pE3 and PKR bind dsRNA with comparable affinities (Schmedt et al., 1995; Ho and Shuman, 1996b) . This means that pE3 would need to be present in a large molar excess of PKR and dsRNA for the sequestration model to account for PKR downregulation. Such a condition could occur in experiments that utilize the expression of pE3 from a transgene (Chang et al., 1995) . In vaccinia virus-infected cells, the levels of pE3 may not be sufficient to sequester all dsRNA activators, but the formation of nonfunctional heterodimers Note. Saccharomyces cerevisiae, strain SFY526, was transfected with the indicated combination of pGAD-AD and pGBT-BD plasmids and assessed for the ability to activate IacZ transcription, as described in Table 1 .
a Yeast transfectants were grown in liquid medium and assayed for ␤-galactosidase activity as described under Materials and Methods. Values represent the mean of three experiments for each combination.
b Fold increase over the values obtained from cotransfections containing GAL4-AD (pGAD424) or GAL4-BD (pGBT9) plasmids. Note. Saccharomyces cerevisiae, strain SFY526, was transfected with the indicated combination of GAL4 activation domain (pGAD-AD) and GAL4 DNA binding domain (pGBT-BD) plasmids and assessed for the ability to activate IacZ transcription, as described under Materials and Methods. Only colonies that contained both plasmids were able to grow on selective medium plates. These were subsequently grown in liquid cultures under the same selection conditions and assayed for ␤-galactosidase using ONPG as substrate (where 1 ഫ ␤-galactosidase ϭ 1 mole ONPG hydrolyzed per minute) (Fields and Song, 1989) . Vectors encoding each of the GAL4-fusion proteins only were transformed together or with each PKR mutant as negative controls. Vectors containing K3L were included as positive controls for interaction with PKR variants. Similarly, SV40LT(84-708) and p53(72-390) were transformed together as a positive control.
b Fold increase over the values obtained from cotransfections containing GAL4-AD (pGAD424) and GAL4-BD (pGBT9) plasmids.
with PKR could prevent PKR activation even in the presence of low concentrations of free dsRNA.
The surprising interaction of pE3 with the carboxylterminus of PKR led us to reexamine the characteristics of PKR itself. The interaction of PKR1±99 and PKR1±152 with PKR367±551 suggests a novel autoregulatory mechanism for PKR, in which the substrate binding domain is masked by the first 99 amino acids in the absence of dsRNA. Such an interaction could provide the molecular mechanism underlying the inactivity of PKR in the absence of dsRNA. Subsequently, interaction of the amino terminal region with dsRNA and the amino terminal region of another PKR molecule could then`ùnmask'' the substrate binding domain, resulting in both activation of the kinase and substrate binding. It is known that autoregulatory domains exist in other kinases. For instance, in protein kinase C (PKC) and myosin light chain kinase (MLCK) the autoregulatory domains resemble the substrate and interact with the substrate binding domain to prevent kinase activity (House and Kemp, 1987; Pearson et al., 1988) . This form of regulation, directed at the active site has been termed intrasteric control (Kemp and Pearson, 1991) . By analogy, we hypothesize that the regulatory domain of PKR from amino acids 1±99 binds at, or near, its own substrate binding site to inhibit kinase activity.
A model illustrating the regulation of PKR, is outlined in Fig. 7 and represents an amalgamation of previously published models (Mathews, 1993; Robertson and Mathews, 1996) with our new data. In the absence of dsRNA, PKR is inactive because amino acids in the dsRNA binding domains interact with and mask the substrate binding domain(s) in a dsRNA-independent manner through protein-protein interaction, depicted as a in Fig. 7 . This is portrayed as occurring via an intramolecular reaction but could just as well occur via an intermolecular reaction between two PKR molecules in which the DRBD of one PKR molecule interacts with the substrate binding domain of a second PKR molecule. In the presence of dsRNA, and the absence of pE3, the amino terminal region of PKR interacts with dsRNA and the amino terminal region of another PKR molecule, unmask- ing the substrate binding domain to yield the active form of the kinase, a dsRNA-bound dimer (depicted as e in Fig. 7 ). In the absence of dsRNA, pE3 is able to interact with the substrate binding domain in the carboxyl-terminal region of PKR maintaining, or stabilizing, an inactive PKR conformation, depicted as b in Fig. 7 . The maintenance of this inactive conformation may, or may not, also involve domains in the amino-terminal region of PKR. In the presence of dsRNA, the interaction of pE3 with the substrate binding domain is reduced, but pE3 is still able to inhibit PKR activity by forming a nonfunctional heterodimer with PKR through the respective dsRNA binding regions (depicted as c in Fig. 7) or by sequestering dsRNA (depicted as d in Fig. 7) . In the presence of higher concentrations of dsRNA, sufficient dsRNA remains free to activate PKR (depicted as e in Fig. 7 ). The above model accounts for the characteristics of pE3 and also provides an explanation of why PKR is inactive in the absence of dsRNA. The model suggests that pE3 is capable of downregulating PKR by three distinct mechanisms and that the relative levels of PKR, pE3, and dsRNA will determine which mechanism is the most significant under different physiological conditions, as will the presence of non-dsRNA activators of PKR, such as heparin. The model is consistent with data presented here, as well with an accumulation of reported data. It is consistent with data from the reticulocyte cell-free translation system, showing that increasing the level of pE3 shifts the dsRNA activation curve (Jagus and Gray, 1994) . It is also consistent with the ability of some variants of PKR that show little ability to bind dsRNA to retain the ability to form dimers (Patel et al., 1996) as well as with the constitutive activity of PKR228±551 (Wu and Kaufman, 1996) .
Our data suggests that pE3 and the amino-terminal of PKR compete for binding to a carboxyl-terminal domain that overlaps the substrate binding domain, and this hypothesis is currently being tested. A prediction from our model is that pE3 should downregulate the activity of the constitutively active variant PKR228±551. However, it has been shown that transient coexpression of pE3 is not able to inhibit PKR228±551 transiently expressed in COS-1 cells, although the relative levels of each protein were not determined and colocalization was not demonstrated (Wu and Kaufman, 1997) . The demonstration of colocalization is important because in vaccinia virusinfected cells, Ͻ10% of the cellular pE3 pool is cytoplasmic (Yuwen et al., 1993) . Alternatively, the inability of pE3 expression to downregulate PKR could reflect the need for pE3 to interact with both amino and carboxy domains to maintain PKR in an inactive state.
The interaction of pE3 with the carboxyl-terminal domain of PKR may also provide vaccinia virus with protection from the activation of PKR by other mechanisms. For instance, it is known that heparin can also activate PKR by interaction with regions that are distinct from the dsRNA binding domains (Patel et al., 1994; George et al., 1996) . The interaction of pE3 with the substrate binding domain of PKR could prevent the activation of PKR by heparin or other cellular activators such as PACT (Patel and Sen, 1998) and thus could be essential for multiplication of the virus. Recent studies from Romano et al. have also shown a direct interaction between pE3 and both the amino-terminal and carboxyl-terminal regions of PKR (Romano et al., 1995) . In addition, these studies indicate that the interaction of pE3 with PKR involves both the DRBD of pE3 as well as a domain in the amino-terminal region of pE3 that is not involved in dsRNA binding. The importance of the amino-terminal region of pE3 is also highlighted by a comparison of the sequence of pE3 with the orf virus OV20.0L gene product, known to confer interferon resistance (Haig et al., 1998) . The OV20.0L gene product is a pE3 homolog that func- tions in vitro to downregulate PKR. This protein shows weak homology to pE3 in the dsRNA binding domain but has a perfectly conserved PPRWF motif in the aminoterminal region.
The interaction of PKR1±99 and PKR1±152 with PKR367±551, which suggests a novel autoregulatory mechanism for PKR, has been anticipated to some extent by prior studies. Similarly, other investigators have concluded that multiple domains within PKR contribute to PKR-PKR interactions. The most significant previous observation is that PKR228±551 is constitutively active, which led to the proposition that the amino-terminal region contains sequences that inhibit kinase activity (Wu and Kaufman, 1997) . In addition, Patel et al., using hexahistidine-tagged full-length PKR bound to Ni 2ϩ -charged Sepharose, concluded that PKR-PKR interaction involves at least two PKR binding domains that function independently and which lie in the amino-and carboxylterminal regions, respectively (Patel et al., 1995) . Similarly, Dever et al. have inferred multiple domain interactions from their demonstration of a direct interaction between PKR and a baculovirus gene product, PK2, that resembles the kinase domains V-XI of PKR . In contrast to our results, Wu et al. were unable to demonstrate an interaction between (Arg296)PKR and PKR1±123 transiently expressed in vivo, but may have been working below the limit of detection in their assay (Wu and Kaufman, 1996) . Similarly, these authors were unable to demonstrate dimerizaton between PKR1±123 and PKR99±551 in vivo although this could reflect the presence of sequences inhibitory to interaction of the amino-and carboxyl-terminal domains by sequences between amino acids 123±367.
Our results demonstrate for the first time that pE3 can interact with a region in the carboxyl-terminal region of PKR, that is the same as, or overlaps with, the substrate binding domain, in a dsRNA-independent manner. Our results have led to a testable model for the regulation of PKR by dsRNA and have also underlined the continued usefulness of viral regulators as tools to dissect the mechanisms regulating PKR activity.
MATERIALS AND METHODS

35
[S]methionine (1000 Ci/mmol) was purchased from Dupont/NEN (Boston, MA). Restriction enzymes, and transcription and translation systems were from Promega Corporation (Madison, WI). All other reagents were of ACS grade or better and purchased from either Sigma Biochemicals (St. Louis, MO) or Fisher Scientific (Pittsburgh, PA) unless otherwise stated. Hela CCL2 were purchased from ATCC (Rockville, MD).
pTM1 plasmid constructs
The construction of pTM1K3L has been described (Carroll et al., 1993; Jagus and Gray, 1994) . pTM1 inserts the 5ЈUTR of EMCV upstream of the open reading frame to produce a transcript that is translated efficiently in vitro in a cap-independent fashion (Moss et al., 1990) . cDNA for E3L was transferred into pTM1 from pHY26 (Yuwen et al., 1993) , kindly supplied by Dr. Bernard Moss.
Yeast two-hybrid plasmid constructs
For the yeast two-hybrid assay E3L, K3L, and PKR variants (Arg296)PKR, des-(297±551)-PKR (PKR1±296), and des-(1±241)-PKR (PKR242±551), were cloned into the vectors pGAD424 and pGBT9 (Clontech) to create fusion proteins with the GAL4-activation domain (AD) and the GAL4-DNA binding domain (BD) domain, respectively. The plasmids pGAD424E3L and pGBT9E3L were constructed by digesting the E3L cDNA from pET11dE3L (Jagus and Gray, 1994) with EcoRI/BamHI and subcloning this fragment into similarly digested pGAD424 and pGBT9 vectors. The construction of pGAD424K3L and pGBT9K3L has been described (Sharp et al., 1997) . The PKR variants (Arg296)PKR, PKR1±296, and PKR242±551 in pGAD424(AD) and pGBT9(BD) were a gift from Dr. Michael Katze, and their construction has been described (Gale et al., 1996) . The mutant des-(100±551)-PKR (PKR 1±99) was constructed by restriction digestion of pGBT9(Arg296)PKR with NcoI/BamHI to remove part of the cDNA encoding amino acids 99±551, followed by ligation using an NcoI/BamHI adaptor. The mutant des-(1±98)-PKR (PKR99±551) was constructed by subcloning an NcoI/BamHI fragment from pGBT9(Arg296)PKR into pGBT9(NcoI) digested with NcoI/BamHI. The mutant des-(1±366)-PKR (PKR367±551) was constructed by deletion of an EcoRI fragment encoding amino acids 1±366.
pGEX4T plasmid constructs
For production of GST-fusion proteins for in vitro binding, pGEX4T-1(NcoI) and pGEX4T-1(NdeI) were constructed by the insertion of an NcoI or NdeI linker within the SmaI site of the polylinker of pGEX4T-1 (Pharmacia). cDNA encoding (Arg296)PKR was obtained from pGBT9(NcoI) following digestion with NcoI/SalI and inserted into NcoI/XhoI digested pGEX4T-1(NcoI) to create pGEX 4T-1(NcoI)(Arg296)PKR. To create PKR1±99 in pGEX4T-1, an NdeI/SalI cDNA fragment from pGBT9 PKR1±99 was subcloned into similarly digested pGEX4T-1(NcoI) vector. PKR99±551 in pGEX4T-1(NcoI) was constructed by subcloning an NcoI/SalI cDNA fragment encoding PKR amino acids 99±551 from pGBT9(NcoI)-PKR99±551 into the NcoI/XhoI site of pGEX4T-1(NcoI). des-(524±551)-PKR (PKR1±523) was constructed from pGAD424(Arg296)PKR by digestion with Bsu 36I/BamHI, followed by digestion with Klenow fragment (Promega) and re-ligation. This encodes a protein with a deletion of the carboxyl-terminal 28 amino acids. The cDNA encoding PKR1±523 was removed from pGAD424PKR1±523 by digestion with NdeI and subcloned into pGEX4T-1(NdeI).
All DNA constructs were sequenced using the PerkinElmer dye termination cycle sequencing ready reaction kit together with the Applied Biosystems 373 DNA sequencer.
Production of recombinant proteins
The pET11a (Novogen) constructs containing PKR mutants (Arg296)PKR, des(361±366)-PKR (PKR⌬6), and PKR242±551, have been described previously . The PKR variants were produced in the E. coli strain, BL21(DE3)pLysS, essentially as described . Recombinant pE3, pK3, and des(75±78)-pK3 (pK3⌬GYID) were expressed and purified as described (Carroll et al., 1993; Jagus and Gray, 1994; Sharp et al., 1997) .
Glutathione S-transferase (GST) and GST-fusion proteins were generated from pGEX4T-1, or pGEX4T-1 constructs, in the E. coli strain BL21. Overnight cultures of BL21 harboring the relevant pGEX4T-1 clone were induced with 100 mM isopropylthiogalactopyranoside for 3 h and extracts prepared essentially as described (Smith and Johnson, 1988) except that cells were resuspended in lysis buffer (50 mM HEPES, pH 7.5; 150 mM NaCl; 1 mM DTE; 20 g/ml aprotinin; 10 g/ml leupeptin; 20 g/ml chymostatin; 1 mM phenylmethylsulfonylfluoride (PMSF); 1 mM EGTA; 0.1 mM EDTA; and 0.1% Triton X-100) prior to sonication.
In vitro binding assays
Two types of in vitro binding assays were used. In the first, binding of proteins to PKR was assessed by their ability to bind to immunopurified PKR. This assay was used for in vitro binding assays involving native PKR and recombinant PKR variants. In the second, binding was assessed by co-recovery of 35 S-labeled proteins with GST-tagged PKR using glutathione±Sepharose beads (GST±glutathione±Sepharose binding assay). This was used for in vitro binding assays involving GST-tagged recombinant PKR variants.
In vitro binding assay using native and recombinant PKR 35 S-labeled pE3 and pK3 were synthesized in a coupled transcription/translation system (TNTQuick, Promega Corporation) containing 35 [S]methionine (500 Ci/ ml). The 35 S-labeled proteins were used in binding assays with native PKR and the recombinant variants (Arg296)PKR, PKR⌬6, and PKR1±296 bound to anti-PKR monoclonal antibody (mAB) [provided by Dr. Ara Hovanessian, Pasteur Institute, Paris, France (Laurent et al., 1985) ] covalently bound to Sepharose beads (Black et al., 1989) . Binding reactions were performed essentially as described in (Sharp et al., 1997) but with the inclusion 1 mg/ml of soybean trypsin inhibitor in all binding and wash buffers. Similar binding assays were performed using recombinant PKR242±551 and anti-PKR polyclonal antibody bound to protein-G agarose, as described previously . All binding experiments included a control without PKR, but with the relevant antibody bound to beads (beads only controls). The volume of beads used reflected the minimum needed to recover Ͼ95% of PKR without giving high backgrounds of nonspecific binding. Bound proteins were eluted in SDS± PAGE sample buffer and analyzed by SDS±PAGE using a Tris-Tricine buffer system as described previously (Schagger and von Jagow, 1987) .
35 S-labeled protein was visualized using the Storm 840 Phosphoimager (Molecular Dynamics Inc., Sunnyvale, CA) and band intensity was quantified using Image-Quant software (Molecular Dynamics Inc. Sunnyvale, CA).
In vitro GST±glutathione±Sepharose binding assay
Bacterial cell extracts containing GST-fusion proteins were prepared as described above. For the analysis of protein interactions, 100 l cell extract (approximately 1 mg protein) was incubated with 25 l of glutathione±Sepharose beads (50% suspension in binding buffer) in 50 mM HEPES, pH 7.5; 150 mM NaCl; 1 mM DTE; 20 g/ml aprotinin; 10 g/ml leupeptin; 20 g/ml chymostatin; 1 mM phenylmethylsulfonylflouride (PMSF); 1 mM EGTA; 0.1 mM EDTA; 0.1% Triton X-100; and 1 mg/ml soybean trypsin inhibitor, in a final volume of 400 l and incubated with rotation at 4°C for 2 h. The beads were washed three times with 1 ml binding buffer and resuspended in 200 l binding buffer. A TNTQuick reaction mix containing 35 S-labeled protein (10 l) was added. The mixture was incubated for 1 h with rotation at 4°C. The beads were washed five times with 1 ml wash buffer (the same as binding buffer except for 400 mM NaCl and 0.5% Triton X-100). The glutathione±Sepharose beads were resuspended in 2ϫ SDS±PAGE sample buffer, incubated at 95°C for 5 min and subjected to 17.5% SDS±PAGE using a Tris±Tricine buffer system, as above.
35 S-labeled protein was visualized and quantified using the Storm 840 Phosphoimager and Image-Quant software (Molecular Dynamics Inc., Sunnyvale, CA).
Western blot analysis of GST-fusion proteins
BL21 cell extracts containing GST or the GST-fusion protein were subjected to 12.5% SDS±PAGE (Jagus, 1987) , transferred to Immobilon-P and blocked with BLOTTO (Johnson et al., 1984) for 1 h at 4°C. Blots were probed with goat anti-GST polyclonal antibody (1 h at 4°C), followed by rabbit anti-goat HRP-conjugated antibody (1 h at 4°C). Specific GST-fusion products were detected using the Amersham ECL kit as per manufacturer's recommendations.
Yeast two-hybrid assay system
The Saccharomyces cerevisiae strain SFY526 was transformed using the lithium acetate method (Gietz et al., 1992) with the indicated combination of GAL4 activation domain, pGAD (AD), and GAL4 DNA binding domain pGBT (BD), plasmids. Only colonies that contained both plasmids were able to grow on SD-agar plates supplemented with leucine and tryptophan. Single colonies were picked and grown overnight in liquid SD medium containing the same amino acids followed by growth in nonselective medium for 3 h and assayed for ␤-galactosidase using o-nitrophenyl ␤-D-galacto-pyranoside (ONPG) as substrate (where 1 U ␤-galactosidase ϭ 1 mole ONPG hydrolyzed per minute) (Fields and Song, 1989) .
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